Metabolic syndrome in polycystic ovary syndrome

Zespół metaboliczny (MS, metabolic syndrome) i zespół policystycznych jajników (PCOS, polycystic ovary syndrome) są często rozpoznawanymi zaburzeniami u kobiet. Częstość występowania zespołu metabolicznego u kobiet z PCOS zależy od zastosowanych kryteriów diagnostycznych. W prezentowanej pracy autorzy rozważają tezę, że przyczyną obu zaburzeń może być insulinooporność, będąca następstwem otyłości brzusznej. Ponadto dokonują przeglądu literatury dotyczącej występowania MS u kobiet z PCOS oraz omawiają wpływ wyboru określonych kryteriów diagnostycznych MS i PCOS na oszacowanie czêstoœci ich występowania.Both metabolic syndrome (MS) and polycystic ovary syndrome (PCOS) are common among women. The exact prevalence of MS in women with PCOS is dependent upon the diagnostic criteria used for each. However, the frequent co-occurrence of both MS and PCOS in women is suggestive of a common aetiology. In this short review article we argue that insulin resistance, as a consequence of abdominal obesity, may represent such a common aetiology. We also review the literature on the prevalence of MS in women with PCOS and consider the impact that the particular criteria used to diagnose both MS and PCOS may have had on these estimates of prevalence

Multidisciplinary management of acromegaly: A consensus

The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly management. Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities are used alone or in combination. Effects of treatment on patient outcomes were considered, along with strategies for optimizing and personalizing therapeutic approaches. Expert consensus recommendations emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence